Animal models of the sporadic form of Alzheimer's disease: Focus on the disease and not just the lesions

Journal of Alzheimer's Disease

Volumn 37, Issue 3, 2013, Pages 469-474

  Iqbal, Khalid ^a   Bolognin, Silvia ^a   Wang, Xiaochuan ^a   Basurto Islas, Gustavo ^a   Blanchard, Julie ^a   Tung, Yunn Chyn ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Asparaginyl endopeptidase; non transgenic rat model of sporadic Alzheimer's disease; protein phosphatase 2A; rat model of sporadic Alzheimer's disease; tau protein; tauopathies

Indexed keywords

BRAIN PROTEIN; I 2 PP2A PROTEIN; I 2CTF PROTEIN; I 2NTF PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; DISEASE MODEL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT MODEL; REVIEW; SPORADIC ALZHEIMER DISEASE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; PROTEIN PHOSPHATASE 2; RATS; TAU PROTEINS;

EID: 84892776614     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130827     Document Type: Review

References (64)

1. Iqbal K, Flory M, Khatoon S, Soininen H, Pirttila T, Lehtovirta M, Alafuzoff I, Blennow K, Andreasen N, Vanmechelen E, Grundke-Iqbal I (2005) Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 58, 748-757.
2. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
3. Wong CW, Quaranta V, Glenner GG (1985) Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are anti-genically related. Proc Natl Acad Sci USA 82, 8729-8732.
4. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82, 4245-4249.
5. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wis-niewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83, 4913-4917.
6. Cork LC, Powers RE, Selkoe DJ, Davies P, Geyer JJ, Price DL (1988) Neurofibrillary tangles and senile plaques in aged bears. J Neuropathol Exp Neurol 47, 629-641.
7. Struble RG, Price DL, Jr., Cork LC, Price DL (1985) Senile plaques in cortex of aged normal monkeys. Brain Res 361, 267-275.
8. Wisniewski HM, Ghetti B, Terry RD (1973) Neuritic (senile) plaques and filamentous changes in aged rhesus monkeys. J Neuropathol Exp Neurol 32, 566-584.
9. Bons N, Rieger F, Prudhomme D, Fisher A, Krause KH (2006) Microcebus murinus: A useful primate model for human cerebral aging and Alzheimer's disease? Genes Brain Behav 5, 120-130.
10. Giannakopoulos P, Silhol S, Jallageas V, Mallet J, Bons N, Bouras C, Delaere P (1997) Quantitative analysis of tau protein-immunoreactive accumulations and beta amyloid protein deposits in the cerebral cortex of the mouse lemur, Microcebus murinus. Acta Neuropathol 94, 131-139.
11. Inestrosa NC, Reyes AE, Chacon MA, Cerpa W, Villalon A, Montiel J, Merabachvili G, Aldunate R, Bozinovic F, Aboitiz F (2005) Human-like rodent amyloid-beta-peptide determines Alzheimer pathology in aged wild-type Octodon degu. Neu-robiol Aging 26, 1023-1028.
12. Ardiles AO, Tapia-Rojas CC, Mandal M, Alexandre F, Kirk-wood A, Inestrosa NC, Palacios AG (2012) Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease. Proc Natl Acad Sci USA 109, 13835-13840.
13. Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, Oster-Granite ML, Neve RL (1989) Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245, 417-420.
14. Quon D, Wang Y, Catalano R, Scardina JM, Murakami K, Cordell B (1991) Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature 352, 239-241.
15. Harada A, Oguchi K, Okabe S, Kuno J, Terada S, Ohshima T, Sato-Yoshitake R, Takei Y, Noda T, Hirokawa N (1994) Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369, 488-491.
16. Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, Goate A, Rossor M, Roques P, Hardy J, et al. (1991) Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353, 844-846.
17. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760.
18. Sorbi S, Nacmias B, Forleo P, Piacentini S, Sherrington R, Rogaev E, St George Hyslop P, Amaducci L (1995) Missense mutation of S182 gene in Italian families with early-onset Alzheimer's disease. Lancet 346, 439-440.
19. Sherrington R, Froelich S, Sorbi S, Campion D, Chi H, Rogaeva EA, Levesque G, Rogaev EI, Lin C, Liang Y, Ikeda M, Mar L, Brice A, Agid Y, Percy ME, Clerget-Darpoux F, Piacentini S, Marcon G, Nacmias B, Amaducci L, Frebourg T, Lannfelt L, Rommens JM, St George-Hyslop PH (1996) Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 5, 985-988.
20. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lan-nfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P (1998) Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705.
21. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 43, 815-825.
22. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 95, 7737-7741.
23. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J (2001) Decreased nuclear beta-catenin, tau hyperphos-phorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20, 27-39.
24. Zilka N, Stozicka Z, Kovac A, Pilipcinec E, Bugos O, Novak M (2009) Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the trans-genic rat model of tauopathy. J Neuroimmunol 209, 16-25.
25. Novak M (1994) Truncated tau protein as a new marker for Alzheimer's disease. Acta Virol 38, 173-189.
26. Ugolini G, Cattaneo A, Novak M (1997) Co-localization of truncated tau and DNA fragmentation in Alzheimer's disease neurones. Neuroreport 8, 3709-3712.
27. Cente M, Filipcik P, Pevalova M, Novak M (2006) Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy. Eur J Neurosci 24, 1085-1090.
28. Filipcik P, Zilka N, Bugos O, Kucerak J, Koson P, Novak P, Novak M (2012) First transgenic rat model developing progressive cortical neurofibrillary tangles. Neurobiol Aging 33, 1448-1456.
29. Salkovic-Petrisic M, Hoyer S (2007) Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: An experimental approach. J Neural Transm Suppl 217-233.
30. Salkovic-Petrisic M, Osmanovic J, Grunblatt E, Riederer P, Hoyer S (2009) Modeling sporadic Alzheimer's disease: The insulin resistant brain state generates multiple long-term mor-phobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta. J Alzheimers Dis 18, 729-750.
31. Chen Y, Liang Z, Blanchard J, Dai CL, Sun S, Lee MH, Grundke-Iqbal I, Iqbal K, Liu F, Gong CX (2013) A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: Similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol 47, 711-725.
32. Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I (1993) Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 268, 24374-24384.
33. Iqbal K, Grundke-Iqbal I, Zaidi T, Merz PA, Wen GY, Shaikh SS, Wisniewski HM, Alafuzoff I, Winblad B (1986) Defective brain microtubule assembly in Alzheimer's disease. Lancet 2, 421-426.
34. Alonso AD, Zaidi T, Grundke-Iqbal I, Iqbal K (1994) Role of abnormally phosphorylated tau in the breakdown of micro-tubules in Alzheimer disease. Proc Natl Acad Sci USA 91, 5562-5566.
35. Alonso AD, Grundke-Iqbal I, Iqbal K (1996) Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 2, 783-787.
36. Alonso AD, Li B, Grundke-Iqbal I, Iqbal K (2006) Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci USA 23, 8864-8869.
37. Li B, Chohan MO, Grundke-Iqbal I, Iqbal K (2007) Disruption of microtubule network by Alzheimer abnormally hyperphos-phorylated tau. Acta Neuropathol (Berl) 113, 501-511.
38. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95, 6448-6453.
39. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
40. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675-688.
41. Arendt T (2009) Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 118, 167-179.
42. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580.
43. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351.
44. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22, 1942-1950.
45. Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K (1995) Phosphatase activity toward abnormally phosphory-lated tau: Decrease in Alzheimer disease brain. J Neurochem 65, 732-738.
46. Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K (1993) Phos-phoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 61, 921-927.
47. Liang Z, Liu F, Iqbal K, Grundke-Iqbal I, Wegiel J, Gong CX (2008) Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome. J Alzheimers Dis 13, 295-302.
48. Tanimukai H, Grundke-Iqbal I, Iqbal K (2005) Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am J Pathol 166, 1761-1771.
49. Wang X, Blanchard J, Kohlbrenner E, Clement N, Linden RM, Radu A, Grundke-Iqbal I, Iqbal K (2010) The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. FASEB J 24, 4420-4432.
50. Arnaud L, Chen S, Liu F, Li B, Khatoon S, Grundke-Iqbal I, Iqbal K (2011) Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I (2) (PP2A)/SET. FEBS Lett 585, 2653-2659.
51. Liu Z, Jang SW, Liu X, Cheng D, Peng J, Yepes M, Li XJ, Matthews S, Watts C, Asano M, Hara-Nishimura I, Luo HR, Ye K (2008) Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase. Mol Cell 29, 665-678.
52. Basurto-Islas G, Grundke-Iqbal I, Tung YC, Liu F, Iqbal K (2013) Activation of asparaginyl endopeptidase leads to tau hyperphosphorylation in Alzheimer's disease. J Biol Chem 288, 17495-17507.
53. Halfon S, Patel S, Vega F, Zurawski S, Zurawski G (1998) Autocatalytic activation of human legumain at aspartic acid residues. FEBS Lett 438, 114-118.
54. Li DN, Matthews SP, Antoniou AN, Mazzeo D, Watts C (2003) Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo. J Biol Chem 278, 38980-38990.
55. Yates CM, Butterworth J, Tennant MC, Gordon A (1990) Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. J Neurochem 55, 1624-1630.
56. Pirchl M, Humpel C (2009) Does acidosis in brain play a role in Alzheimer's disease? Neuropsychiatrie 23, 187-192.
57. Bolognin S, Blanchard J, Wang X, Basurto-Islas G, Tung YC, Kohlbrenner E, Grundke-Iqbal I, Iqbal K (2012) An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. Acta Neuropathol 123, 133-151.
58. Iqbal K, Wang X, Blanchard J, Grundke-Iqbal I (2011) A non-transgenic rat model of sporadic Alzheimer's disease. In Animal Models for Neurodegenerative Disease, Avila J, Lucas J, Hernandez F, eds. Royal Societyof Chemistry, pp. 274-283.
59. Blanchard J, Wanka L, Tung YC, Cardenas-Aguayo Mdel C, LaFerla FM, Iqbal K, Grundke-Iqbal I (2010) Pharmaco-logic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Abeta and tau pathologies in 3xTg-AD mice. Acta Neuropathol 120, 605-621.
60. Lawlor PA, Bland RJ, Das P, Price RW, Holloway V, Smithson L, Dicker BL, During MJ, Young D, Golde TE (2007) Novel rat Alzheimer's disease models based on AAV-mediated gene transfer toselectively increase hippocampal Abeta levels. Mol Neurodegener 2, 11.
61. Holzer M, Bruckner MK, Beck M, Bigl V, Arendt T (2000) Modulation of APP processing and secretion by okadaic acid in primary guinea pig neurons. J Neural Transm107, 451-461.
62. Liu R, Wang JZ (2009) Protein phosphatase 2 Ain Alzheimer's disease. Pathophysiology 16, 273-277.
63. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the protea-some. Neuron 43, 321-332.
64. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791.